ENDV

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 2/13/2017
Contact Info
  • 6320 Canoga Avenue
  • 15th Floor
  • Woodland Hills, CA 91367

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001528172
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2008
Employees 16 a/o Nov 13, 2012
Company Officers/Contacts
Alan Collier CEO, Interim CFO
Michael Mann President
Don Calabria COO
Steven Barnes SVP, Inv. Rel.
Leonard Makowka Chief Med. Officer
Company Directors
Alan Collier Chairman
Service Providers
Accounting/Auditing Firm
Rose, Snyder & Jacobs
15821 Ventura Blvd.
Suite 490
Encino, 91436
United States
 
Securities Counsel
Frank J. Hariton, Esq.
1065 Dobbs Ferry Road
White Plains, NY, 10607
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Hanover Portfolio Acquisitions Inc. until 5-2014
ENDV Security Details
Share Structure
Market Value1 $6,539,898 a/o Mar 29, 2017
Authorized Shares 500,000,000 a/o Mar 07, 2017
Outstanding Shares 155,711,859 a/o Mar 07, 2017
-Restricted 101,250,828 a/o Mar 07, 2017
-Unrestricted 54,461,031 a/o Mar 07, 2017
Held at DTC 34,692,700 a/o Mar 07, 2017
Float 622,092 a/o May 18, 2015
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
Equity Stock Transfer
Shareholders
Shareholders of Record 317 a/o May 17, 2016
Short Selling Data
Short Interest 19,914 (148.3%)
Feb 15, 2017
Significant Failures to Deliver Yes - Reg SHO

1Market Value calculated only for respective security